PRESS RELEASE

BIO-Europe Spring® 2026: Partnering Momentum Builds as Global Biopharma Leaders Set Course for Lisbon

MUNICH, GERMANY – March 16, 2026. The global biopharmaceutical community is preparing to gather in Lisbon, Portugal, for the 20th edition of BIO-Europe Spring®, the premier springtime partnering conference for the industry, taking place March 23–25, 2026.

More than 3,700 attendees from over 2,000 companies, including leading pharmaceutical firms, innovative biotech companies, and global investors, are expected along Lisbon’s shores for one of Europe’s most important meeting points for life science innovation and dealmaking. Held alongside LSX Europe as part of Life Sciences Spring Innovation Week, this year’s event will create an expanded platform for strategic discussions across biotech, pharma, and investment communities.

Partnering has opened and is now in full swing, with over 20,000 one-to-one meetings expected, reinforcing BIO-Europe Spring’s role as a vital hub for investment, collaboration, and cross-border engagement across the global life sciences ecosystem.

“Portugal’s life sciences sector has developed into a dynamic and internationally connected ecosystem, driven by strong research, innovative biotech companies, and growing investment activity,” said Joana Branco, Director of Innovation and Ecosystem at Biocant Park, co-host sponsor of BIO-Europe Spring 2026. Filipa Sacadura, Director General of P-Bio, also co-host sponsor, added: “Hosting BIO-Europe Spring 2026 in Lisbon is a fantastic opportunity to showcase Portugal’s innovation landscape and connect our biotech community with global industry leaders, investors, and partners.”

“We are excited to bring the 20th annual edition of BIO-Europe Spring to Lisbon, a city whose life sciences ecosystem continues to gain international recognition,” said Claire Macht, Director of BIO-Europe Spring. “With strong participation from biotech innovators, pharmaceutical leaders, and global investors, BIO-Europe Spring 2026 will provide an essential platform to explore new partnering opportunities and help shape the next wave of life science innovation.”

BIO-Europe Spring 2026 will focus on partnering and dealmaking from early-stage innovators to mature biotech companies. The event recently strengthened its collaboration with YVC Collective, a network of more than 600 emerging life sciences venture capital professionals across Europe. Through this partnership, YVC Collective members help review applications for the conference’s Startup Spotlight and Presenting Company programs, ensuring promising early-stage companies gain exposure to investors and industry leaders at a pivotal stage of development.

Key Sessions and Events at BIO-Europe Spring 2026:

The 20^th annual BIO-Europe Spring conference will feature an engaging program curated by EBD Group (an Informa company) offering company presentations, panel discussions, and networking opportunities designed to foster collaboration across the life sciences value chain.

A featured panel, “Piecing Together the Therapeutic Landscape with Analyst Insights”, will leverage leading analyst intelligence and data-driven insights to provide a deep dive into the evolving biopharma ecosystem. Moderated by Daniel Chancellor (Evaluate), the panelists Samuel Bennett (Novo Nordisk), Hakan Goker (M Ventures), Laura Lane (Eli Lilly and Company), Toby Richardson (Johnson & Johnson), and Jan Van den Bossche (Andera Partners) will explore emerging trends, market dynamics, and investment opportunities across key therapeutic areas, offering strategic insights to navigate 2026 and beyond.

Another ever-popular, recurring session, “Day in the Life of an Experienced Dealmaker”, will offer a firsthand look at the current state of the life sciences landscape. Anton Gueth (EVOLUTION Life Science Partners), Evonne Sepsis (ESC Advisors), Claudio Costa-Neto (Jeito Capital), Evan Lippman (Teva Pharmaceuticals), and Chris Sheldon (GSK) will share strategies for navigating the complex biotech and pharma ecosystem.

The program will also spotlight emerging innovators through the Startup Spotlight, a live pitch competition showcasing promising biotech startups. Selected companies will present their innovations to the BIO-Europe Spring audience and a panel of expert judges, offering insight into the next generation of life science innovation.

Partnering and Registration for BIO-Europe Spring 2026

One-to-one meetings will be powered by partneringONE®, an industry-standard platform that enables delegates to search, request, schedule, and conduct meetings efficiently. To enhance access and extend engagement beyond the in-person event, the conference will continue with two days of virtual partnering on March 31–April 1, allowing participants to connect regardless of time zone or travel constraints.

Registration information for BIO-Europe Spring is available online. Discounted rates are still available until March 20, 2026.

Additional Links and Information

BIO-Europe Spring is organized by EBD Group, an Informa company.

For more information and live updates, please visit the conference website at: https://informaconnect.com/bioeurope-spring and follow BIO-Europe Spring 2026 on LinkedIn.

About Informa and EBD Group

EBD Group’s mission is to help collaborations get started across the life science value chain. Our range of partnering conferences has grown to become the largest and most productive conference portfolio in the industry. Each one of our landmark events, held in key life science markets around the world, is powered by our state-of-the-art partnering software, partneringONE, that enables delegates to efficiently identify and engage with new opportunities via one-to-one meetings. Today, our events and those of our sister organization, LSX (BIO-Europe, BIO-Europe Spring®, LSX Europe, Biotech Showcase™, LSX USA, Investival Showcase USA, ChinaBio® Partnering Forum, Asia Bio Partnering Forum, LSX Nordic, BioEquity Europe, Investival Showcase EU, and the European Lifestars Awards), annually attract more than 15,000 senior life science executives who engage in over 50,000 one-to-one partnering meetings. These vital one-to-one engagements are the wellspring of deals that drive innovation in our industry.

EBD is an Informa company. Informa is a leading international Live B2B Events, B2B Digital Services, and Academic Markets Group. Informa is a member of the FTSE 100 and works in over 30 countries.

For more information, please visit: https://informaconnect.com/partnering-investment-strategy/

Media Contacts:

MC Services AG
+49 89 2102280
contact@mc-services.eu

Informa
Paul Gilbertson
paul.gilbertson@informa.com

NVision and Aarhus University Awarded Innovation Fund Denmark Grant to Advance Clinical Translation of Quantum-Enhanced MRI

The €5.4 million (40m DKK) investment for the MIRAQLE project supports the development of scalable, clinically deployable hyperpolarized MRI for early liver cancer diagnostics.
 

ULM, Germany & AARHUS, Denmark — March 16, 2026 — NVision, a quantum technology company, and Aarhus University have secured a €5.4 million (40m DKK) grant for the MIRAQLE project under Denmark’s Grand Solutions in Quantum Technologies program. The award is a significant endorsement of NVision’s quantum hyperpolarization technology and establishes a direct route for quantum-enabled diagnostics to move from the lab to the clinic.

Cancer is often detected too late. Although standard MRI scans are good at showing a tumor’s size and location, they miss the metabolic activity that reveals how aggressive the disease is or whether a treatment is working.

MIRAQLE aims to change this. Researchers from the MR Research Centre at Aarhus University and NVision Imaging Technologies will develop a new type of MRI platform capable of visualizing cancer metabolism. By boosting the imaging agent’s MRI signal, metabolic activity can become visible during a routine MRI scan. This could make it possible to detect serious disease earlier and to monitor treatment effects far more precisely than is currently possible.

Expanding Clinical Applications to Liver Cancer

NVision’s research partnerships are rapidly expanding to cover a diverse range of medical applications. While research at Memorial Sloan Kettering Cancer Center is focused on monitoring treatment efficacy in various cancers, NVision’s recently established research hub at the University of Cambridge Department of Radiology allows for the exploration of both oncology and non-oncology applications, including general liver disease and multiple sclerosis.

The new research project at Aarhus University builds on this momentum with a dedicated focus on liver cancer. In hepatocellular carcinoma, it can be difficult for doctors to distinguish between benign changes and early-stage liver cancer, often delaying diagnosis until the disease is advanced. With NVision’s technology, doctors will be able to not only detect the disease earlier but also assess how aggressive it is.

“Our expanding network of research partnerships enables us to advance the use of hyperpolarized MRI across a broad spectrum of critical medical applications—from early disease detection and stratification to monitoring oncology treatments and tailoring therapies based on metabolic response,” said Prof. Myriam Chaumeil, Head of Research and MIRAQLE project lead at NVision. “Liver cancer is a compelling application because hyperpolarized MRI can reveal the metabolic activity that drives tumor growth in real time, providing insights that conventional imaging cannot offer.”

“We will be able to see how the cancer behaves, not just where it is. This could change the feedback cycle from months to days, making a decisive difference to when and how patients are treated,” said Professor Christoffer Laustsen, project leader and Head of the MR Research Centre at Aarhus University.

Up to 100,000 Times More Sensitive

NVision’s proprietary technology, POLARIS, is based on quantum physics and can make MRI scans up to 100,000 times more sensitive than those available today. This means that even very small changes on the cellular level can be detected. At the same time, the scan is carried out entirely without radioactive radiation – unlike many current methods used in cancer diagnostics. POLARIS is being developed so that it can be used in regular hospitals and integrated into existing MRI infrastructure.

Driving this clinical translation is the goal of the MIRAQLE project, which spans everything from laboratory research to preclinical and clinical studies in hepatocellular carcinoma to demonstrate the technology’s diagnostic value.

Strong European Backing

MIRAQLE strengthens NVision’s robust portfolio of publicly funded European research consortiums. The project joins a growing list of successful initiatives aimed at advancing and commercializing quantum medical technology, including CHARM, HYPERCELL, MAGSENSE, Q-AID, Que-MRT, and most recently, the AURORA project. Together, these consortiums represent more than €35 million in public grant funding secured since 2022 to support the transition of NVision’s technology from the lab to the clinic.

About NVision Imaging

NVision Imaging was founded in 2015 and is headquartered in Ulm, Germany. By leveraging advances in quantum physics, NVision enables real-time visualization of metabolism on standard MRI, aiming to set a new standard for faster drug development, earlier diagnosis, and better therapy decisions. Learn more at nvision-imaging.com.

Contact:

Leah Wiedenmann
NVision
leah.wiedenmann@nvision-imaging.com

 

Media Release – Ad-hoc announcement pursuant to Art. 53 LR                          

 

Medacta Group reports record results in Full Year 2025 and upgrades mid-term guidance

 

• FY 2025 revenue accelerated to Euro 683.8 million, up 18.5% in c.c.¹ or 15.8% in Euro
• Adjusted EBITDA grew by 19.1% to Euro 190.8 million
• Adjusted EBITDA margin advanced to 29.0% in c.c. ¹ up 190 bps yoy
• Net profit rose by 31.0% yoy to Euro 95.5 million incl. one-off gains
• Operating cash flow grew by 42.5% to Euro 152.7 million
• The Board of Directors is proposing a distribution of CHF 1.10 per share (2024: CHF 0.69), an increase of 59.4% yoy
• Outlook 2026: Medacta is targeting a revenue growth in the range of 10% to 14% in constant currency and an expansion of the adjusted EBITDA margin of around 50bps vs. the prior year (27.9%), in constant currency, subject to unforeseen events.
• Mid-term outlook: Revenue compound annual growth rate (CAGR) (2024–2027E) in constant currency is expected to range between 12% and 15%, with a gradual improvement of the adjusted EBITDA margin vs. 2025, in constant currency, subject to unforeseen events.

 

CASTEL SAN PIETRO, 13 March 2026 – Medacta Group SA (“Medacta”, SIX: MOVE) today announces its full year 2025 results.

Francesco Siccardi, CEO of Medacta, commented: “I am very pleased to report another year of strong organic sales growth in the high teens, together with a significant expansion of our adjusted EBITDA margin. These industry leading results confirm the unique position of Medacta. Our vigorous focus on differentiating innovations for minimally invasive techniques and personalized solutions, the surgeon-specific structured medical education and the constant expansion of our sales force are the key pillars of our successful strategy. I thank the entire Medacta team for its efforts in delivering such excellent results.”

 

Our achievements in 2025

2025 marks Medacta’s 10 years of success of Kinematic Alignment in combination with Medacta’s Ball-in-Socket design for total knee replacement. This was a milestone that underscores our dedication to sustainable innovation and improving patient outcome. Kinematic Alignment is a surgical technique designed to restore the natural knee function to its pre-arthritic state. This innovative approach has gained the attention and continues to find a growing consensus in the global orthopedic community.  

At the beginning of March 2025, Medacta announced the acquisition of Parcus Medical, a Florida based specialist provider of sports medicine and arthroscopy solutions. The acquisition excellently complements Medacta’s portfolio in sports medicine. Parcus Medical is integrated into Medacta’s Sportsmed within the Extremities business line. As part of the acquisition, Medacta also took over Parcus’ Medical US manufacturing site in Sarasota (Florida), allowing Medacta to also be vertically integrated in Sportsmed and to have the first non-Swiss based manufacturing plants. The acquisition of Parcus Medical contributed approximately 1.5% to Group revenue in 2025.

In 2025, Medacta progressed to further strengthen and optimize its supply chain. Medacta has almost finalized its new fully automated warehouse in Italy. This new setup will facilitate and reduce handling costs primarily in Europe, Middle East and Africa (EMEA).

In early September 2025, Medacta completed the first phase of the planned extension of its production and office site in Rancate, Ticino, Switzerland.

The company will continue its expansion plan in 2026, aiming to accommodate increased demand to support future growth, while creating numerous new jobs.

In 2025, Medacta added another 258 employees globally, reaching 2’165 employees in total. 

 

Key figures

(Euro million, except for earnings per share data)	31.12.2025	31.12.2024
Revenues	683.8	590.6
Gross profit	458.7	399.4
Profit for the period	95.5	72.9
Alternative performance measures
(Euro million)	31.12.2025	31.12.2024
EBITDA	201.5	156.6
Adjusted EBITDA*	190.8	160.2
Adjusted EBITDA margin*	27.9%	27.1%
Operating cash flow	152.7	107.1
Free cash flow	15.7	8.3

 

(Euro million, except for employees)	31.12.2025	31.12.2024
Total assets	917.6	792.2
Total equity	456.6	379.7
Equity ratio	49.8%	47.9%
Number of employees	2’165	1’907

* Adjusted in 2025 for business combinations (Euro -11.3 million) and MDR transition costs (Euro 0.6 million). The reconciliation is provided in the “Alternative Performance Measures” section of the 2025 Annual Report.

 

Sustained above-market growth of 18.5% in constant currency

In 2025, Medacta recorded Group revenue of Euro 683.8 million, an increase of 18.5% in constant currency and an increase of 15.8% in Euro.

Medacta reported another year of outstanding growth in all geographic markets and continued superior growth across all business lines. This was achieved by the constant launch of our differentiating innovations across all business lines, our continued efforts in medical education and the attraction of new surgeons supported by our expanded sales force. 

Substantial revenue growth across all geographic areas

Medacta achieved substantial growth rates across all geographies. The largest contributions to growth came from Asia Pacific and North America, growing 23.0% and 19.0% respectively, followed by EMEA increasing 15.2%, all in c.c.. Latin America, which is the smallest geographic area, advanced a superb 42.2% in c.c..

Revenue distribution by geographic area:

(Euro million)	FY 2025	FY  2024	Growth in Euro	Growth in constant currency
EMEA*	327.5	283.7	15.4%	15.2%
North America	204.5	179.3	14.1%	19.0%
Asia Pacific	134.8	115.1	17.1%	23.0%
Latin America	17.0	12.4	36.7%	42.2%
TOTAL	683.8	590.6	15.8%	18.5%

* Europe, Middle East and Africa

Excellent revenue expansion across all product lines

Hip revenues rose again in double-digits by 11.9% in c.c., to Euro 270.5 million, with particularly outstanding performance in Asia Pacific and North America. The growth was mainly the result of Medacta’s excellent Anterior Minimally Invasive Surgery (AMIS) platform, which allows an easily reproducible technique that delivers significant benefits to patients, surgeons as well as healthcare systems ^[1,2,3].

Knee revenues advanced by another outstanding 20.7% in c.c. to Euro 284.1 million. All geographic regions contributed to this growth, but mainly attributable to North America as well as EMEA. Next to Medacta’s personalized Kinematic Alignment platform MyKA, GMK SpheriKA, the first knee implant specifically designed for the Kinematic Alignment technique, promoted this excellent performance. In 2025, the global roll-out of GMK SpheriKA further advanced including the UK, Canada and Japan. 2025 saw an additional boost in the adoption of the NextAR Knee system as well as for cementless and SensiTiN, Medacta’s low-ion-release, options.

Extremities, which include both, Shoulder and Sportsmed, delivered another notable revenue growth of 46.2% in c.c. to Euro 72.1 million with both sub-businesses contributing to this great progress. In particular, Medacta’s Shoulder System, supported by advanced technologies such as Medacta’s MyShoulder patient-specific cutting guidesas well as NextAR Shoulder Augmented Reality surgical application delivered an excellent performance, achieving market leading position in key geographies.

Spine revenues increased by 12.2% in c.c. to Euro 57.0 million. The good acceleration was strongly sustained by Medacta’s technologies, particularly by NextAR Spine, and the Rod Optimizer platform, which support surgeons in designing the optimal surgical strategy based on each patient’s individual anatomy and helps to streamline the surgical workflow. An expansion was seen across all geographies but was primarily supported by EMEA as well as Asia Pacific.

Revenue distribution by business line:

(Euro million)	FY  2025	FY 2024	Growth in Euro	Growth in constant currency
Hip	270.5	247.3	9.4%	11.9%
Knee	284.1	241.2	17.8%	20.7%
Extremities**	72.1	50.3	43.4%	46.2%
Spine	57.0	51.8	10.2%	12.2%
TOTAL	683.8	590.6	15.8%	18.5%

** Extremities include Shoulder and Sportsmed revenues

Gross profit

In 2025, gross profit advanced to Euro 458.7 million compared to Euro 399.4 million in 2024 reflecting an increase of 14.8% year-on-year. The corresponding gross profit margin was 67.1% compared to 67.6% over the same period in the previous year. The softening was the result of unfavorable FX impacts, which were partially offset by operational efficiencies realized. 

Adjusted EBITDA margin

Adjusted EBITDA grew to Euro 190.8 million compared to Euro 160.2 million in 2024, representing a year-on-year increase of more than 19%.  The corresponding 2025 adjusted EBITDA margin climbed to 29.0% in constant currency or 27.9% in Euro. This compares to an adjusted EBITDA margin of 27.1% in Euro in 2024. The margin expansion was the result of efficiency gains and lower costs, mainly in sales and marketing as compared to the same time period last year. Reported EBITDA was Euro 201.5 million compared to Euro 156.6 million, an increase of 28.7% year-on-year.

Adjusted EBIT

Adjusted EBIT for the period rose to Euro 114.3 million compared to Euro 94.4 million in 2024, reflecting an increase of more than 21% against the previous year. The corresponding adjusted EBIT margin was 16.7% in 2025 compared to 16.0% in the prior year, representing an improvement of 70 basis points year-on-year.

Net profit for the year

In 2025, the net financial result was Euro -9.8 million versus Euro -3.1 million in the previous year. The Group’s effective tax rate was 17.2% in 2025.

Profit for the period increased by 31.0% to Euro 95.5 million compared to Euro 72.9 million in 2024. The increase was the result of a higher operating profit and the bargain purchase gain recognized on the Parcus acquisition. In 2025, the corresponding net profit margin was 14.0% compared to 12.3% in 2024.

Cash flow

Medacta delivered a cash flow from operating activities of Euro 152.7 million in 2025 compared to Euro 107.1 million in the same period in 2024, representing an increase of 42.5% year-on-year.

Capital expenditures amounted to Euro 137.0 million in 2025 versus Euro 98.9 million compared to 2024. A good 80% of capital expenditures were investments in instruments and production expansions to sustain future growth.

Free cash flow was Euro 15.7 million compared to Euro 8.3 million in 2024, reflecting an improvement of almost 90%.

Solid balance sheet

Medacta’s balance sheet remained robust at the end of December 2025. Total assets increased to Euro 917.6 million vs. Euro 792.2 million at the end of 2024. The equity ratio strengthened to 49.8% at the end of December 2025 compared to an equity ratio of 47.9% at the end of December 2024.

Net debt to adjusted EBITDA ratio improved to 0.88x at the end of 2025 compared to 0.99x at the end of 2024.

Dividend proposal

At the Annual General Meeting on 5 May 2026, the Board of Directors will propose a dividend distribution of 1.10 CHF per share (0.69 CHF in 2024), an increase of 59.4% against the prior year. 

 

Outlook 2026

Medacta is targeting a revenue growth in the range of 10% to 14% in constant currency and an expansion of the adjusted EBITDA margin of around 50bps vs. the prior year (27.9%), in constant currency, subject to unforeseen events.

Mid-term outlook

Revenue compound annual growth rate (CAGR) (2024–2027E) in constant currency is expected to range between 12% and 15%, with a gradual improvement of the adjusted EBITDA margin vs. 2025, in constant currency, subject to unforeseen events.

For further financial details, please refer to the 2025 Annual Report, which can be accessed at: https://www.medacta.com/EN/financial-reports-and-presentations

Webcast Today at 3:00 p.m. (CET)

Medacta Group SA will present its Full Year 2025 results during a webcast today at 3:00 p.m. (CET). The call will be hosted by Francesco Siccardi (CEO) and Corrado Farsetta (CFO) and will be held in English.

Live-Link:  https://87399.choruscall.eu/links/medacta260313.html

Dial-in numbers for conference call only:

Belgium: +32 28948063
Denmark: +45 32727525
France: +33 170918704
Germany: +49 6917415712
Ireland: +353 15269444
Italy: +39 02 802 09 11
Spain: +34 917699498
Sweden: +46 850510030
Switzerland: +41 225954728
UK: +44 1 212818004
USA: +1 718 7058796

  

Contact

Medacta
Anja Pomrehn
Group VP Sustainability and Investor & Media Relations
Phone: +41 91 696 14 95
pomrehn@medacta.ch

 

About Medacta

Medacta is a global key player specializing in the design, production, and distribution of innovative, personalized, and sustainable solutions for joint replacement, sports medicine, and spine surgery. Established in 1999 in Switzerland, Medacta is committed to improving the care and well-being of patients and maintains a strong focus on healthcare sustainability. Through close collaboration with expert surgeons globally, continuous investments in R&D, and the adoption of cutting-edge technologies, Medacta’s innovation prioritizes minimally invasive surgery and personalized solutions for every patient. Through the M.O.R.E. Institute, Medacta supports surgeons with a comprehensive and tailored program dedicated to the advancement of medical education. Medacta is headquartered in Castel San Pietro, Switzerland. Follow us on Medacta.com, Medacta TV, YouTube, LinkedIn and X.

 

Disclaimer

This media release has been prepared by Medacta Group SA (‘Medacta’ and together with its subsidiaries, ‘we’, ‘us’ or the ‘Group’). The information contained in the media release does not purport to be comprehensive and is not to be taken as containing any securities advice, recommendation, offer or invitation to subscribe for, purchase or redeem any securities regarding Medacta.

 Forward-looking information

This media release has been prepared by Medacta and includes forward-looking information and statements concerning the outlook for its business. These statements are based on current expectations, estimates and projections about the factors that may affect its future performance. These expectations, estimates and projections are generally identifiable by statements containing words such as ‘expects’, ‘believes’, ‘estimates’, ‘targets’, ‘plans’, ‘outlook’ or similar expressions. Although Medacta believes that its expectations reflected in any such forward-looking statement are based upon reasonable assumptions, it can give no assurance that those expectations will be achieved.

 Related Trademarks

Medacta Group Related Trademarks are registered at least in Switzerland. The products and services listed below may not be all-inclusive, and other Medacta products and services not listed below may be covered by one or more trademarks. The products and services below may be covered by additional trademarks not listed below. Note that Swiss trademarks may have foreign counterparts. AMIS®, GMK® SpheriKA, MyShoulder®, MyKA™, SensiTiN™, NextAR™, NextAR™ Spine.

 Notes

1)Alternative Performance Measures:

This media release contains certain financial measures of historical performance that are not defined or specified by IFRS, such as “constant currency”, “EBITDA”, “adjusted EBITDA”, “Free Cash Flow”, “adjusted Free Cash Flow”, “Net Debt” and “Leverage”. These Alternative Performance Measures (APMs) should be regarded as complementary information to, and not as a substitute for the IFRS performance measures. For definitions of APMs, together with reconciliations to the most directly reconcilable IFRS line items, please refer section headed “Alternative Performance Measures” of the 2025 Annual Report. The 2025 Annual Report is available and can be accessed at:

 https://www.medacta.com/EN/financial-reports-and-presentations .

 Above-market revenue growth:

This press release contains information that refers to “above-market revenue growth”, which is in reference to data from The Orthopaedic Industry Annual Report® published by Orthoworld® Inc., published May 2025.     

References

[1] Vasina PG, Rossi R, Giudice GM, Palumbi P. Hip arthroposthesis through the anterior minimally invasive approach. Sphera 2010;6(12) – Speciale Ortopedia

[2] Christofilopoulos P, Roussos C, Lädermann A, Lübbeke A, Hoffmeyer P. Socioeconomic aspects of total hip arthroplasty. A comparison between anterior minimally invasive surgery and standard lateral approach. Poster at the 12th EFORT Congress, Copenhagen, Denmark: 1-4 June 2011.

[3] Sebečić B, Starešinić M, Culjak V, Japjec M. Minimally invasive hip arthroplasty: advantages and disadvantages. Med Glas (Zenica). 2012 Feb;9(1):160-5. PMID: 22634930.

Galimedix Therapeutics earns milestone payment in ophthalmology partnership

with Théa Open Innovation

• Galimedix receives milestone payment for successful completion of Phase 1 trial with orally administered GAL-101
• Phase 1 results show the compound to be clinically safe and well-tolerated, with a pharmacokinetic profile supporting advancing to Phase 2
• Payment provides Galimedix with an important operational runway to proceed with plans for additional clinical development in Alzheimer’s disease and other indications

Kensington, MD, USA and Munich/Martinsried, Germany, March 12, 2026 – Galimedix Therapeutics, Inc. (“Galimedix”), a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize and reshape the treatment of serious eye and brain diseases, today announced the achievement of a key milestone in its collaboration with Théa Open Innovation (“TOI”), a subsidiary of ophthalmic specialty pharmaceutical company, Laboratoires Théa. Galimedix has successfully completed the Phase 1 trial with orally administered GAL-101, which has triggered an undisclosed milestone payment to the Company. The eye drop formulation of GAL-101 is currently in Phase 2 development for the treatment of geographic atrophy, a severe form of dry age-related macular degeneration (AMD).

“We are pleased with the achievement of this milestone for GAL-101,” said Céline Olmiere, Director of Théa Open Innovation. “This highly innovative drug candidate has the potential to significantly impact dry AMD patients who are at risk of going blind. Our collaboration with Galimedix supports continued commitment to building a strong cutting-edge and diversified ophthalmological portfolio for eye care specialists and their patients around the world.”

“We are gratified to have the strong support of Théa Open Innovation in developing GAL-101 and excited to see such solid results in the Phase 1 trial,” said Alexander Gebauer, MD, PhD, Co-founder and Executive Chairman of Galimedix Therapeutics. “Importantly, this milestone payment provides Galimedix with significant operational runway and will allow us to advance our development plans for GAL-101 in Alzheimer’s disease and other supportive R&D work.”

As previously announced, the Phase 1 results showed oral GAL-101 to be well tolerated and clinically safe, with an excellent pharmacokinetic profile, effectively crossing the blood-brain barrier, strongly supporting advancing the oral formulation in Phase 2 development in Alzheimer’s disease and other indications.

In March 2023, TOI and Galimedix entered into a strategic partnership in ophthalmology for the development and commercialization of GAL-101 in Europe, the Americas, the Middle East and Africa. Under the terms of the agreement, Galimedix received an upfront technology access fee and is eligible to receive further success-based milestone payments as well as royalties on net sales. TOI is fully funding the remaining development of GAL-101 in dry AMD and will take charge of the registration and commercialization of the drug in ophthalmology. Galimedix is responsible for the conduct of the mid-stage clinical trials. TOI also made a direct investment into Galimedix, demonstrating its strong interest in the value of the Galimedix pipeline, including in Alzheimer’s disease.

About GAL-101
GAL-101 is a small molecule targeting misfolded amyloid beta (Aβ) monomers and thus preventing the formation of toxic Aβ oligomers and protofibrils. It is being developed in both oral and topical (eye drops) formulations. Many studies have indicated that these Aβ aggregates are a major underlying cause of neurodegenerative diseases of the brain and retina, and recent approvals of anti-Aβ drugs have also validated them as a key target in Alzheimer’s disease. GAL-101 initially is being developed for the treatment of dry age-related macular degeneration (AMD), glaucoma, and Alzheimer’s disease.

In pre-clinical testing, the compound has been shown to prevent and eliminate all forms of toxic Aβ species while leaving healthy Aβ forms intact. GAL-101 has also demonstrated the potential for neuroprotection and for symptomatic alleviation in pre-clinical models of Alzheimer’s disease. Additionally, orally available GAL-101 has shown no antibody-specific immunological side effects (e.g., ARIA), very low systemic toxicity, robust storage stability, and easy and inexpensive manufacturing. Strong efficacy has also been demonstrated in relevant ophthalmic pre-clinical models, protecting neuronal retinal cells from toxic damage. In Phase 1 testing, both the oral and eye drop forms of GAL-101 demonstrated an excellent safety and tolerability profile. In addition, oral GAL-101 was shown to effectively cross the blood-brain barrier. The eDREAM Phase 2 study (NCT06659549) in dry AMD/geographic atrophy with GAL-101 eye drops is ongoing.

About Galimedix Therapeutics, Inc.
Galimedix is a Phase 2 clinical-stage private biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases. Founded by a seasoned and highly dedicated team of bio-entrepreneurs, pharmaceutical executives and scientists, Galimedix’s groundbreaking small molecules offer the hope of changing the course of disease where amyloid beta (Aβ) plays a role, such as in Alzheimer’s disease, dry age-related macular degeneration and glaucoma, Galimedix’s initial areas of focus. For more information, please visit our website at https://www.galimedix.com and follow us on LinkedIn.

About Théa and Théa Open Innovation
Théa is the leading independent European pharmaceutical company specializing in the research, development, and commercialization of eye-care products. Based in Clermont-Ferrand, France, this family-owned company has continued to expand by opening more than 35 affiliates and offices in Europe, North Africa, North and South America, and the Middle East. Its products are available in 75 countries around the world.
Théa Open Innovation, a subsidiary of Théa, is dedicated to set up partnerships with biotech/pharma companies and academic institutions to help bring the most innovative products in eye care to the market.
To learn more, visit www.thea.com and www.theaopeninnovation.com.

Contact 
Alexander Gebauer, MD, PhD
Galimedix Therapeutics, Inc.
Co-founder and Executive Chairman
info@galimedix.com

Media inquiries:

Anne Hennecke	U.S.
MC Services AG	Laurie Doyle
Tel: +49 (0)170 7134018	Tel: +1-339-832-0752
galimedix@mc-services.eu

Herrsching, Germany / Maseru, Lesotho (12/03/2026) – Canify AG, a company specializing in the processing and marketing of medical cannabis products, and MG Health Limited, Africa’s first EU-GMP certified producer of medical cannabis flowers and extracts, today announce their planned merger. In a signed Memorandum of Understanding (MoU), both companies have agreed to expand their successful two-year collaboration into a combined holding structure. The group will be a fully vertically integrated medical cannabis platform spanning EU GMP-certified production, pharmaceutical processing, and multi-market distribution, with commercial presence in more than 7 countries including Germany, the United Kingdom, Australia, and Poland, as well a unique global supplier network.

The two companies have worked closely together since Q4 2024, when MG Health began supplying Canify with medical cannabis flower on a consistent basis. That proven supply relationship now forms the operational foundation for a full merger.  “Mutual trust has grown out of our good working relationship – and so it is only logical to take our cooperation to the next level,” says Sascha Mielcarek, CEO of Canify AG. “We share not only quality standards, but also a common attitude: patients are at the center of everything we do. Our shared vision is to create a globally active pharmaceutical company with a clear focus on the highest quality standards and clinical innovation.”

The planned merger will create a vertically integrated structure that is unique in the European medical cannabis market. The combined group will control every critical step in the pharmaceutical value chain: from EU GMP-certified flower cultivation and extraction at MG Health’s facility in Lesotho, through pharmaceutical processing regulatory management, and multi-channel distribution via Canify’s established network of pharmacy partnerships and its direct-to-patient Canify Clinics platform.

MG Health’s production platform provides the combined group with a significant structural cost advantage. Operating at 2,000 metres altitude in the Maluti Mountains of Lesotho, the facility benefits from optimal growing conditions, low energy costs, and year-round natural light, enabling pharmaceutical-grade production at a fraction of the cost of European indoor facilities. Beyond operational efficiency, MG Health has invested meaningfully in the local community, creating hundreds of sustainable jobs, expanding local infrastructure, and delivering education and development programmes for employees, their families, and surrounding communities.

“As a company that puts people first, we don’t see economic success as an end in itself, but as a means to enable positive and sustainable change within our society,” says Andre Bothma, CEO of MG Health. “This principle shapes our daily actions in Lesotho – from responsible, sustainable management and long-term employment prospects to targeted education initiatives. In Canify, we have found a partner who shares these values and will carry them forward with us.”

“The merger gives us the opportunity to align our processes across the entire value chain with expertise and regulatory frameworks—and thus complement each other perfectly,” explains Mielcarek. For example, Canify’s existing international supplier network can be optimally aligned with MG Health’s expanded production and processing capacities. “At the same time, with MG Health, we are strengthening an approach that combines pharmaceutical excellence, social responsibility, and environmental sustainability.”

The combined group will pursue an ambitious international growth strategy. Building on active export supply chains in Australia, the United Kingdom and Poland besides the core market in Germany, the merger memorandum includes planned market expansion into Switzerland and further European markets.

Completion of the merger is subject to the finalisation of definitive agreements, and receipt of all necessary regulatory approvals. However, both parties are convinced that this will be completed timeously and that this first step will lay the foundation for sustainable growth, innovative care concepts, and long-term stable patient care.

About Canify AG:
Canify AG is a licensed pharmaceutical company specializing in medical cannabis. Canify’s products are based on scientific data, cutting-edge technology, and a commitment to helping patients. Canify’s approach is to make the cannabis business as easy and convenient as possible for pharmacies and wholesalers. Canify also offers customized production and market access solutions for third-party providers, setting standards in terms of quality, production capacity, and delivery times. In addition, Canify treats patients with individual cannabis therapy via telemedicine or in medical practices under the Canify Clinics brand. Canify AG consistently meets the highest standards of European GMP guidelines and offers transparency and traceability from cultivation to the patient.

About MG Health Limited:
MG Health is a vertically integrated manufacturer of medical cannabis flowers and extracts. The production facility is located at an altitude of 2,000 meters in the pristine mountainous landscape of the Kingdom of Lesotho in southern Africa. In this pure and untouched environment, MG Health produces safe and effective medical cannabis products of consistently high quality in accordance with the strictest pharmaceutical standards. MG Health is the first EU GMP-certified African medical cannabis company and currently exports its products to the United Kingdom, Australia, Germany, South Africa, and the Czech Republic. MG Health focuses on implementing a plant-to-patient philosophy and building a sustainable future for all.

Further information is also available on our websites:
www.canify.com / www.canify-pharma.de

www.mghealth.com

Contacts for press inquiries:
Kathrin Konyen                                               Luke van der Nest
Press officer Canify AG                                  Commercial Director  MG Health Ltd
press@canify.com                                                          info@mghealth.com
+49(0)173/6790782                                                      +266 5928 3540
 

MindMaze Therapeutics Appoints HealthTech Veteran Zach Henderson as CEO to Accelerate Global Commercial Scale

Former Rune Labs and Glooko executive to lead MindMaze’s next phase of growth, focusing on U.S. market expansion and the delivery of scalable, AI-driven neurorestorative care.

Geneva, Switzerland – March 12, 2026 – MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics, or the Company), a global leader in brain technology and precision neurotherapeutics, today announced the appointment of Zach Henderson as Chief Executive Officer. Mr. Henderson joins at a pivotal inflection point as the Company invests in scaling its existing commercial presence, focused on accelerating adoption of its FDA-cleared platform in the United States to address the widening supply-demand gap in neurological care.

With over 30 years of experience, Mr. Henderson has a proven track record of scaling healthcare technology platforms and driving significant recurring revenue growth. His most recent role as Chief Commercial Officer at Rune Labs and his prior tenure as CEO of PKG Health underscore his expertise in commercializing AI-driven solutions for complex chronic conditions like Parkinson’s.

“MindMaze has built the industry’s most rigorous clinical foundation. Our mission now is to translate that scientific leadership into widespread market adoption,” said Walid Hanna, Chairman of the Board. “Zach’s operational depth and success across global markets make him the ideal leader to drive our commercial expansion and deliver value to our shareholders.”

The global healthcare system faces a critical shortage of neurologists and specialized therapists (PT/OT), leaving millions of patients with stroke, Parkinson’s disease, and Alzheimer’s with insufficient access to recovery. MindMaze is redefining this paradigm by shifting care from episodic, clinic-bound sessions to continuous, data-driven neurorestoration accessible at scale in both clinical and home settings.

“I am honored to lead MindMaze as we solve one of healthcare’s most pressing capacity challenges,” said Zach Henderson. “By digitizing the neuro-restorative journey, we are providing a scalable solution to a global shortage of specialized care providers. We are redefining the standard of care for tens of millions of patients worldwide.”

Mr. Alexandre Capet has been appointed Chief Operating and Strategy Officer continuing his service as a standing member of the Company’s Executive Committee.

About MindMaze Therapeutics
MindMaze Therapeutics (SIX: MMTX) is a global leader in brain technology, dedicated to redefining the recovery trajectory for patients with neurological platform-based digital treatments. By integrating advanced software, proprietary sensors, and AI-driven data analytics, MindMaze Therapeutics provides a seamless continuum of care from the acute hospital phase to outpatient treatment to the home-based therapy. The Company’s FDA-cleared and CE-marked neurotherapeutics are designed to address the systemic shortage of specialized clinicians, offering scalable, reimbursable solutions for stroke, Parkinson’s disease, and other brain disorders. With a commitment to rigorous clinical validation and a robust R&D pipeline, MindMaze Therapeutics is operationalizing the future of neurorestorative medicine.

For more information, visit www.mindmazetherapeutics.com.

Media & Investor Contacts
Investor Relations:
Jeremy Meinen, Chief Financial Officer
ir@mindmazetherapeutics.com
Media Inquiries:
VSC for MindMaze Therapeutics
mindmazetherapeutics@vsc.com 

DISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as “believe,” “assume,” “expect,” “intend,” “may,” “could,” “will,” or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, among others, business, economic, financial, regulatory, and competitive factors, as well as the Company’s ability to execute its strategy. This communication is provided as of the date hereof, and MindMaze Therapeutics undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.